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Abstract
Aims/hypothesis: Midlife obesity is a risk factor for dementia. We investigated the
impact of obesity on brain structure, metabolism, and cerebrospinal fluid (CSF) core
Alzheimer’s disease (AD) biomarkers in healthy elderly.
Methods: We selected controls from ADNI2 with CSF AD biomarkers and/or fluo-
rodeoxyglucose positron emission tomography (FDG-PET) and 3T-MRI.Wemeasured
cortical thickness, FDG uptake, and CSF amyloid beta (Aβ)1-42, p-tau, and t-tau lev-
els.Weperformed regression analysesbetween thesebiomarkers andbodymass index
(BMI).
Results: We included 201 individuals (mean age 73.5 years, mean BMI 27.4 kg/m2).
Higher BMI was related to less cortical thickness and higher metabolism in brain
areas typically not involved in AD (family-wise error [FWE] <0.05), but not to AD CSF
∗Data used in preparation of this article were obtained from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). As such, the investigators within the ADNI con-
tributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found at:
http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf.
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biomarkers. It is notable that the impact of obesity on brain metabolism and structure
was also found in amyloid negative individuals.
Conclusions/interpretation: In the cognitively unimpaired elderly, obesity has differ-
ential effects on brain metabolism and structure independent of an underlying AD
pathophysiology.
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body mass index, cerebrospinal fluid Alzheimer’s disease biomarkers, fluorodeoxyglucose PET,
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1 INTRODUCTION
Obesity has become a global pandemic with multiple adverse clinical
consequences.1 Accumulating evidence demonstrates that cognition is
affected by an excess of body adiposity in both adults and children.2-5
Epidemiological studies also indicate that midlife obesity increases the
risk of progression tomild cognitive impairment (MCI) andAlzheimer’s
disease (AD).6,7 On the contrary, higher body mass index (BMI) in late-
lifemightbeprotective.8 This obesityparadoxmightbeassociatedwith
the confounding effect of weight loss in preclinical AD.9
The exact mechanisms leading to cognitive impairment and neu-
rodegeneration in persons with an excess of body adiposity remain
to be fully elucidated.7 Animal models suggest a significant contri-
bution of obesity and obesity-related metabolic disturbances to AD
pathophysiology.7,10-13 In contrast, humanstudies assessing the impact
of obesity on amyloid and tau pathology report conflicting findings
both in vivo and in post-mortem studies. Thus, higher BMI has been
related to higher, but also to lower, ADburden.14-18 On the other hand,
obesity might contribute to neurodegeneration by mechanisms unre-
lated to AD. Obesity is a state of peripheral low-grade chronic inflam-
mation, and it is frequently associated with an abnormal peripheral
sensitivity to insulin effects. In experimental models, obesity-related
peripheral inflammation has been linked to blood-brain barrier dys-
function, neuroinflammation, and neurodegeneration, whereas central
insulin resistance has been associated with impaired synaptic plas-
ticity and memory.19-21 Furthermore, obesity is a strong risk factor
for hypertension, type 2 diabetes, and dyslipidemia, and it is a well-
established cerebrovascular risk factor.1
Brain atrophy and brain hypometabolism are well-recognized non-
specific biomarkers of neurodegeneration. Several studies have shown
an association between high BMI and brain atrophy.22 Fewer studies
have assessed the relationship between obesity and brain metabolism
in cognitively healthy subjects.23-28 In contrast to the consistent brain
atrophy reported in magnetic resonance imaging (MRI) studies, these
works have reported higher brain metabolism with respect to lean
controls.23-26,28
None of the above-mentionedworks, however, integrated biochem-
ical and neuroimaging data. Multimodal studies might be useful to
better understand the pathophysiological pathways involved in the
deleterious impact of an excess of body adiposity on brain health
and to explore whether obesity contributes to neurodegeneration by
amyloid-dependent or independent mechanisms.
Taking advantage of a large multicenter cohort, the Alzheimer’s
Disease Neurodegenerative Initiative (ADNI), we aimed to investigate
the relationship between BMI and brain structure, brain metabolism,
and core AD cerebrospinal fluid (CSF) biomarkers in cognitively unim-
paired elderly. To examine whether the effects of obesity on brain
structure and metabolism are independent of an AD process, we also
investigated the aforementioned relationships in amyloid negative
individuals.
2 METHODS
2.1 Study participants
Data used in the preparation of this article were obtained from the
ADNI database (adni.loni.usc.edu). The ADNI was launched in 2003
by the National Institute on Aging (NIA), the National Institute of
Biomedical Imaging and Bioengineering (NIBIB), the U.S. Food and
Drug Administration (FDA), private pharmaceutical companies, and
non-profit organizations, as a $60 million, 5-year public-private
partnership. The primary goal of ADNI has been to test whether
serial MRI, positron emission tomography (PET), other biological
markers, and clinical and neuropsychological assessment can be
combined to measure the progression of MCI and early AD. The
principal investigator of this initiative is Michael W. Weiner, MD, VA
Medical Center and University of California, San Francisco. ADNI is
the result of efforts of many co-investigators from a broad range of
academic institutions and private corporations, and subjects have been
recruited from >50 sites across the United States and Canada. More
information can be found in the acknowledgments section (see also
http://adni-info.org/).
For the present study, we included all cognitively healthy controls
from ADNI2 with biometric and biochemical data and either (a) a 3T
MRI and a fluorodeoxyglucose (FDG) PET scan with a time-lapse inter-
val between both scans of less than 1 year or (b) CSF measurements
of amyloid beta (Aβ 1-42), total tau (t-tau), and phosphorylated tau
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(p-tau). Supplementary Figure 1 shows the study flowchart. All human
subjects included in the study followed the inclusion criteria from
ADNI that requires an informed consent.
Demographic (age, sex, educational level), clinical (presence of type
2 diabetes [T2D], usual medication), neuropsychological (Alzheimer
Disease Assessment Scale-Cognitive score [ADAS-Cog], Clinical
Dementia Rating Sum of Boxes [CDR-SB], and Mini-Mental State
Examination [MMSE]), anthropometric (height, weight, and systolic
and diastolic blood pressure), and laboratory data (fasting plasma
glucose, cholesterol, and triglycerides) were downloaded from the
ADNI database. BMI was calculated as weight in kilograms divided by
height in meters squared.
2.2 MRI analysis
The details of MRI acquisition and pre-processing are available
elsewhere (http://adni-info.org/). We processed the MRIs using the
cortical reconstruction pipeline of Freesurfer v5.1. (http://surfer.nmr.
mgh.harvard.edu) as described previously.32,33 Before the statisti-
cal analyses, we checked the estimated surfaces in order to detect
and correct possible segmentation errors. We applied a smooth-
ing kernel of 15 mm. To assess atrophy in AD vulnerable areas,
we extracted the mean cortical thickness values for each subject
from a well-validated region of interest, the Dickerson’s finger-
print (ie, medial temporal cortex, inferior temporal gyrus, temporal
pole, angular gyrus, superior frontal gyrus, superior parietal lobule,
supramarginal gyrus, precuneus, and inferior frontal sulcus of both
hemispheres).34
2.3 18-Fluorodeoxyglucose PET scan analysis
Thedetails of positron-emission tomography (PET) acquisitionandpre-
processing are available elsewhere (http://adni-info.org/). Briefly, PET
scans were co-registered and averaged. Subsequently, the image was
standardized to 1.5 mm cubic voxels and smoothed with an 8 mm full
width at half maximum (FWHM) kernel to produce an image of a uni-
form resolution. Then, each FDG-PET image was spatially normalized
to each subject’s Freesurfer anatomical MRI space using a rigid-body
transformation and intensity-scaled by the pons-vermis region as pre-
viously described.35 The resulting images were visually-inspected in
order to check for35 errors and projected to the middle point of the
cortical ribbon.36 Before performing statistical analyses, the resulting
surfaces were smoothed using a kernel of 10 mm FWHM to obtain
equivalent relative smoothing kernels for the PET and cortical thick-
ness (CTh) maps. Surface-based smoothing introduces less bias than
volume-based methods and substantially improves the reliability and
the intersubject variability.37 In order to assess the brainmetabolism in
AD vulnerable areas, we extracted themean FDG standardized uptake
value ratios (SUVRs) for each subject from a well-validated region of
interest, the Landau signature (ie, left and right angular, temporal, and
posterior cingulate regions).35
Research in Context
1. Systematic review: The authors reviewed the litera-
ture using PubMed, meeting abstracts, and presenta-
tions. Obesity has been identified as a risk factor for
dementia and is related to brain atrophy in several stud-
ies. However, few works have explored the relationship
betweenobesity andbrainmetabolism. Theseworks have
reported higher brain metabolism with respect to lean
controls. In addition, the association between obesity
and cerebrospinal fluid (CSF) Alzheimer’s disease (AD)
biomarkers is inconclusive. No previous multimodal stud-
ies have assessed the relationship betweenBMI and brain
metabolism, structure, and AD biomarkers in cognitively
healthy elderly. This relevant bibliography is appropri-
ately cited.
2. Interpretation: Our findings demonstrate that obesity
presents a significant but divergent effect on corti-
cal structure and brain metabolism independent of AD
pathology.
3. Future directions: In this article we propose a framework
for conducting additional studies such as: (a) the role of
inflammation on the brain metabolic alterations found in
obesity, and (b) the AD-independent mechanisms leading
to cognitive impairment and dementia in subjects with
obesity.
2.4 Cerebrospinal fluid (CSF) data
The details of the CSF analysis have been described in http://adni-info.
org. Briefly, pristine aliquotswere examinedby the validated andhighly
automated Roche Elecsys electrochemiluminescence immunoassays.
Thismethodologyminimizes inter-run variability forAβ1-42, t-tau, and
p-tau levels in CSF. The cutoff used for Aβ1-42was 977 pg/mL.38
2.5 Statistical methods
Demographic, clinical, anthropometric, and cognitive variables were
analyzed by R statistical software (version 3.4.4; http://www.r-project.
org).
To assess the relationship between BMI and both the neuroimag-
ing and core AD CSF biomarkers, we performed regression analyses.
For the neuroimaging metrics, we first executed vertex-wise correla-
tion analyses between BMI and both CTh and FDGuptake in thewhole
sample including age, sex, and triglycerides, variables significantly cor-
related with BMI, as covariates. The figures show only those results
that survived the family-wise error (FWE) correction at P < 0.05 as
implemented in Freesurfer. Second, we performed regression analyses
between BMI and MRI and FDG-PET AD signatures, mean CTh and
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TABLE 1 Demographic, clinical, neuropsychological,
anthropometrical, and biochemical data for the study subsets (CSF
andMRI-PET samples)
CSF sample
MRI-PET
sample P
N 178 168
Gender=Male (%) 89 (50.0) 85 (50.6) .998
Age, mean (SD) 73.41 (6.25) 73.65 (6.30) .726
BMI, mean (SD) 27.36 (4.02) 27.15 (3.92) .627
SBP, mean (SD) 133.77 (15.90) 134.87 (16.04) .523
DBP, mean (SD) 73.61 (9.23) 74.86 (10.08) .231
Glycemia, mean (SD) 99.79 (18.19) 98.20 (17.89) .413
Total cholesterol, mean
(SD)
189.25 (36.69) 190.59 (36.34) .734
Triglycerides, mean (SD) 133.97 (72.08) 138.55 (79.70) .574
Years of Education, mean
(SD)
16.57 (2.46) 16.52 (2.56) .856
APOE ε4= Positive (%) 48 (27.0) 49 (29.2) .737
MMSE, mean (SD) 29.00 (1.27) 29.03 (1.27) .828
ADAS11, mean (SD) 5.87 (3.13) 5.70 (2.91) .617
ADAS13, mean (SD) 9.10 (4.56) 9.00 (4.42) .834
T2D= Positive (%) 31 (17.4) 23 (13.7) .420
CSF Aβ1-42, mean (SD) 1386.95
(656.68)
1397.40
(661.87)
.887
CSF t-tau, mean (SD) 235.61 (89.71) 236.15 (92.48) .958
CSF p-tau, mean (SD) 21.48 (9.10) 21.54 (9.10) .955
SUVRs and the core ADCSF biomarkers including age, sex, and triglyc-
erides as covariates.
To further assess a potential influence of preclinical AD, we per-
formed regression analyses, with and without including the core AD
CSF biomarkers as covariates, and stratified analyses in the amyloid-
positive and amyloid-negative groups separately.
3 RESULTS
We included 201 subjects (50.3%male) in the studywith amean age of
73.5 years (range: 56.2 to 89.1) and a mean BMI of 27.4 kg/m2 (range:
20.0 to 39.1). Therewere nodifferences in these variables between the
subset of patients with MRI and FDG (N = 168) and the subset of sub-
jects with CSF (N = 178). Table 1 summarizes the demographic, clin-
ical, neuropsychological, anthropometrical, and biochemical data for
the two study subsets. Therewerenodifferences in anyof the variables
between the subsamplewithCSFbiomarkers and thewhole sample.Of
thewhole sample, 29.2%of participants hadabnormal levels ofAβ1-42.
BMI was weakly correlated with fasting triglycerides levels (r = 0.18,
P= 0.02). There was no correlation between BMI and education, base-
line cognitive performance, systolic or diastolic blood pressure, total
cholesterol, or fasting glucose levels.
3.1 Higher body mass index (BMI) is associated
with increased cerebral metabolism and cortical
atrophy in areas not typically involved in Alzheimer’s
disease (AD)
Figure 1A and 1B show the association between BMI and FDG uptake
across the cortical mantle. Higher BMI was associated with higher
cerebral FDG uptake in widespread brain areas including the inferior
temporal lobe of the left hemisphere, insula of the right hemisphere
and anterior cingulate,medial frontal, andorbitofrontal regions of both
hemispheres (FWE < 0.05). Figure 1C and D show the association
between BMI and CTh in the same individuals. Higher BMI was asso-
ciated with lower cortical thickness in areas that included superior
medial frontal regions of the right hemisphere and inferior temporal
zones of the left hemisphere (FWE< 0.05).
The areas of increased brain metabolism and less cortical thickness
showed little overlap. Of note, these regions also had very little overlap
with the Landau’s and Dickerson’s signature, respectively. Moreover,
BMIwas not significantly associatedwith CTh orwith FDG in theDick-
erson’s and Landau’s signatures (P = 0.41 and P = 0.50, respectively)
(supplementary Figure 2).
3.2 Higher BMI is not associated with CSF AD
biomarkers
We found no relationship between BMI and CSF Aβ1-42 (P = 0.15),
CSF p-tau (P = 0.43), or CSF total tau (P = 0.35, respectively) levels
(Figure 2). Neither did we find any association between BMI and CSF
biomarkers when analyzing the amyloid-positive and amyloid-negative
groups separately (supplementary Figure 3).
3.3 The impact of BMI on neuroimaging
biomarkers is independent of AD pathophysiology
To test the influence of AD biomarkers on neuroimaging outcomes,
we repeated the analyses including Aβ1-42 and t-tau as covariates,
and we performed stratified analyses in amyloid-positive and amyloid-
negative individuals. The inclusion of CSF biomarker levels did not
affect the results, which remained qualitatively the same (supplemen-
tary Figure 4).
The stratified analyses in the amyloid-positive and amyloid-negative
participants separately, despite the smaller sample size, showed that
higher BMI was related to higher FDG uptake in both groups. Brain
atrophy in relation to higher BMI was significant only in the amyloid-
negative group (Figure 3).
4 DISCUSSION
In this study, we found a differential influence of obesity on brain struc-
ture and brain metabolism. Higher BMI was associated with increased
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F IGURE 1 Cortical vertex-wise pattern of the relationship between BMI and both FDG (A) and CTh (C) adjusted by age, gender, and
triglycerides. Only clusters that survived family-wise error corrected P-value< 0.05 are shown. Red-yellow scale color is used to display positive
correlations in relation to FDG uptake and blue-green scale is used for negative correlations in relation with CTh. Scatter plots in B andD show the
relationship between BMI andmean FDG uptake andmean CTh in the cluster ROIs in A and C
brain metabolic activity, but at the same time with less cortical thick-
ness. The affected zones did not overlap with the typical AD vulner-
able areas. Furthermore, BMI was not associated with core CSF AD
biomarkers and the results were also found in amyloid-negative partic-
ipants, suggesting that these changes are independent of an underlying
AD pathophysiology.
We first analyzed the relationship between brain metabolism and
BMI. Only two cross-sectional and three longitudinal previous studies
have assessed the relationship between brain metabolism and obesity
in middle-aged individuals.23,24,26-28 The results of the cross-sectional
studies were conflicting.Wang et al. observed higher brainmetabolism
in theparietal cortices of 20middle-agedparticipantswithmorbidobe-
sity as compared with 10 lean controls, whereas Volkow et al. found
a negative relationship between BMI and FDG uptake in prefrontal
areas.27,28 Of note, only 3 of the 21 participants evaluated in the lat-
ter study had BMIs in the obesity range.27 All three longitudinal stud-
ies assessed brain metabolism in middle-aged individuals with morbid
obesity before and after bariatric surgery–induced weight loss.23,24,26
Marques et al. described brain hypermetabolism in 17 women with
severe obesity as compared with 16 lean controls, which normalized
after weight loss.23 Brain metabolism normalization in this study was
associated with cognitive improvement.23 Tuulari et al. and Rebelos
et al. did not observe differences in brain metabolism between par-
ticipants with morbid obesity and controls in fasting conditions, but
both found higher insulin-stimulated FDG uptake.24,26 The low num-
ber of controls in these two studies (n = 7 and n = 12, respectively)
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F IGURE 2 Scatter plots showing the lack of relationship between BMI and ADCSF biomarkers. From left to right: Aβ1-42, p-tau, and t-tau
might have limited the statistical power to detect subtle differences
during fasting conditions. Nonetheless, in both studies, brainmetabolic
abnormalities normalized after bariatric surgery.24,26 Only one pre-
vious study assessed the relationship between BMI and brain FDG
uptake in healthy elderly. This study, also in the ADNI cohort, included
222 participants and also showed higher brain metabolic activity in
relation to higher BMI mostly in women.25 Altogether, our results and
the aforementioned studies suggest that obesity is associated with
increased FDG uptake in the brain.
We also evaluated the relationship between obesity and cortical
thickness in the same sample. In accordancewith previous results from
our group and others, we observed cortical thinning associated with
increasing BMI.9,22,39-41
The regions affected by atrophy and higher metabolism in our
study showed little overlap with the typical vulnerable AD regions.
It is important to note that we did not find any association between
BMI and the CTh and brain metabolism in two of the most commonly
used AD signatures.34,35 Furthermore, we did not find any associa-
tion between BMI and CSF amyloid or tau levels, and the inclusion of
CSF biomarkers in the analyses yielded qualitatively the same results.
Finally, in the analyses stratified by amyloid status, amyloid-negative
participants showed a pattern of changes similar to that observed in
the whole cohort. Altogether, these results suggest that the aforemen-
tioned cortical changes are independent of an underlying AD process.
Other cross-sectional studies in cognitively normal controls
showed greater amyloid and tau burden associatedwith lower late-life
BMI.17,18,42 On the contrary, the only two previous longitudinal studies
showed greater amyloid deposition late in life in relation with mid-life
obesity.15,16 Discrepancies between mid-life and late-life studies
might be explained by reverse causation (ie, AD-related weight loss
in preclinical AD), selection and survival biases (ie, higher mortality
and dementia risk in persons with obesity might determine that only
those specially protected against obesity consequences survived
and/or maintained normal cognition late in life), or by the existence
of additive and/or competing risk (ie, obesity not only promote neu-
rodegeneration throughout AD pathophysiological mechanisms and
therefore only those with lower AD burden remain cognitively normal
late in life).9,29,30,43 Thus, although a contribution of obesity to AD
pathophysiological processes cannot be completely ruled out, our
results reinforce the notion that obesity affects brain metabolism and
structure bymechanisms independent of AD pathophysiology.
The mechanisms mediating the structural and metabolic brain
abnormalities in individuals with obesity are beyond the objectives
of the present work, and deserve further research.47 The finding
of higher brain metabolism with increased BMI is relatively unex-
pected.We hypothesize that this findingmight reflect obesity-induced
neuroinflammation and astrogliosis. Of interest, in the aforemen-
tioned studies with subjects who underwent bariatric surgery,
higher FDG cerebral uptake correlated with markers of systemic
inflammation.23,24 In this sense, although brain glucose metabolism is
considered a marker of neuronal activity, FDG-PET signal has recently
been demonstrated to be also located in astrocytes.44 In addition,
animal studies combining FDG-PET and PET with tracers for activated
microglia confirmed a highly co-localized signal of increased glucose
metabolism and neuroinflammation in both wild-type aging mice and
AD transgenic mice.45,46 It is interesting to note that in wild-type mice
an uncoupling between glucose metabolism and neuroinflammation
was observed at older ages, that is, neuroinflammation persisted
but glucose metabolism returned to baseline values. This late-life
uncoupling has been attributed to the progression of age-dependent
neurodegeneration.46 In this same line, a triple-tracer study per-
formed in AD transgenic mice showed age-dependent microglial
activation, which positively correlates with amyloid load and brain
metabolism. Nonetheless, in this study, brain hypermetabolism was
observed especially at younger ages, and declined in relation to
increasing amyloid burden, thus suggesting that synaptic dysfunction
might mask inflammation-related hypermetabolism.45 In the same
line, in our study, the relationship between obesity and increased
brain metabolism was attenuated in participants with preclinical AD.
Further studies are required to better understand the contribution of
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F IGURE 3 Cortical vertex-wise pattern of the relationship between BMI and both FDG and CTh depending on their Aβ1-42 status. Only
clusters that survived family-wise error corrected P-value< 0.05 are shown. Red-yellow scale color is used to display positive correlations in
relation with FDG uptake and blue-green scale is used for negative correlations in relation with CTh
peripheral and central nervous system inflammation or other mecha-
nisms to the brainmetabolic changes, which are present in obesity.
This study has limitations. First, as it is cross-sectional, a causal
relationship between BMI and brain neuroimaging abnormalities
cannot be assessed. Second, there is a significant bias in the ADNI
cohort, which excluded participants with large vascular burden and
comprises mainly Caucasian participants. This selection bias might
explain the healthier than expected phenotype of cognitively healthy
ADNI participants with obesity. Of note, we did not find the expected
correlation between BMI and fasting plasmatic glucose and systolic
or diastolic blood pressure. This bias precludes the generalization of
our results to broader obese populations. Third, there is evidence
that both insulin resistance and variability in fasting glucose lev-
els can affect FDG uptake among cognitively normal middle-aged
individuals.47,48 Given that there is sparse data available in ADNI
to better characterize the glucometabolic status in our subjects, the
degree of increase in FDGuptake reported here needs to be confirmed
among individuals with more detailed evaluation of glucose tolerance
status and appropriate measures of insulin sensitivity. Nonetheless, it
should be underscored that no significant correlation between fasting
glucose levels and BMI was found in our cohort, and that the impact
of insulin sensitivity on brain metabolism was not consistent among
studies.23,24,26,48,49 Fourth, other relevant variables closely related to
body weight, including dietary habits and physical activity, which have
been previously related to brain health, are not available in ADNI.
In conclusion, obesity presents a significant and divergent effect on
cortical structure and brain glucose metabolism in areas not typically
involved in AD and independent of the AD pathophysiological process.
Further studies are needed to explore the association of these changes
with obese-related neuroinflammation or other mechanisms.
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